FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315433651> ?p ?o ?g. }

• W4315433651 endingPage "e98" @default.
• W4315433651 startingPage "e88" @default.
• W4315433651 abstract "Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskeletal diseases are largely unknown. We aimed to assess the incidence of breakthrough SARS-CoV-2 infection, compare rates of moderate-to-severe COVID-19 with any severe infection event, and evaluate predictors of moderate-to-severe COVID-19 outcomes in patients treated with rituximab.We did a retrospective cohort study in all rituximab-treated patients with rheumatic and musculoskeletal diseases in a single centre in Leeds, UK between March 1, 2020 (the index date), and April 1, 2022. Adults aged 18 years and older, who fulfilled classification criteria for established rheumatic and musculoskeletal diseases, and received therapy with at least one rituximab infusion between Sept 1, 2019 (6 months before the pandemic in the UK), and April 1, 2022, were eligible for inclusion in the study. SARS-CoV-2 infection was defined by antigen test or PCR. COVID-19 outcomes were categorised as mild (from ambulatory to hospitalised but not requiring oxygen support) or moderate-to-severe (hospitalised and requiring oxygen support or death). The primary outcome was breakthrough COVID-19 infection, which was defined as an infection occurring 14 days or more after the second vaccine dose. Predictors of moderate-to-severe COVID-19 outcomes were analysed using Cox regression proportional hazards.Of the 1280 patients who were treated with at least one cycle of rituximab since Jan 1, 2002, 485 (38%) remained on rituximab therapy on April 1, 2022. Of these patients, 400 fulfilled all inclusion criteria and were included in our final analysis. The mean age at the index date was 58·9 years (SD 14·6), 288 (72%) of 400 patients were female and 112 (28%) were male, 333 (83%) were White, and 110 (28%) had two or more comorbidities. 272 (68%) of 400 patients had rheumatoid arthritis, 48 (12%) had systemic lupus erythematosus, 48 (12%) had anti-neutrophil cytoplasmic antibody-associated vasculitis, and 46 (12%) had other rheumatic and musculoskeletal diseases. During the study, 798 rituximab cycles were administered. Of the 398 (>99%) of 400 patients with vaccine data, 372 (93%) were fully vaccinated. Over the 774·6 patient-years of follow-up, there was an incremental increase in all SARS-CoV-2 severity types over the three pandemic phases (wild-type or alpha, delta, and omicron), but most infections were mild. The rates of moderate-to-severe COVID-19 were broadly similar across these three variant phases. Of 370 patients who were fully vaccinated and with complete data, 110 (30%) had all severity type breakthrough COVID-19, 16 (4%) had moderate-to-severe breakthrough COVID-19, and one (<1%) died. In the post-vaccination phase (after Dec 18, 2020), the incidence rates of all severity type and moderate-to-severe COVID-19 were substantially lower in those who were fully vaccinated compared with unvaccinated or partially vaccinated individuals (22·83 per 100 person-years [95% CI 18·94-27·52] in those who were fully vaccinated vs 89·46 per 100 person-years [52·98-151·05] in those who were partially vaccinated or unvaccinated for infections of all severities, and 3·32 per 100 person-years [2·03-5·42] in those who were fully vaccinated vs 25·56 per 100 person-years [9·59-68·10] in those who were partially vaccinated or unvaccinated for moderate-to-severe infections). The rate of moderate-to-severe COVID-19 was broadly similar to other severe infection events in this cohort (5·68 per 100 person-years [95% CI 4·22-7·63]). In multivariable Cox regression analysis, factors associated with an increased risk of moderate-to-severe COVID-19 were the number of comorbidities (hazard ratio 1·46 [95% CI 1·13-1·89]; p=0·0037) and hypogammaglobulinaemia (defined by a pre-rituximab IgG concentration of <6 g/L; 3·22 [1·27-8·19]; p=0·014). This risk was reduced with each vaccine dose received (0·49 [0·37-0·65]; p<0·0001). Other factors, including concomitant prednisolone use, rituximab-associated factors (eg, rituximab dose and time to vaccination since last rituximab dose), and vaccine-associated factors (eg, vaccine type and peripheral B-cell depletion) were not predictive of moderate-to-severe COVID-19 outcomes.This study presented detailed analyses of rituximab-treated patients during various phases of the COVID-19 pandemic. In later stages of the pandemic, the SARS-CoV-2 breakthrough infection rate was high but severe COVID-19 rates were similar to any severe infection event rate in patients who were vaccinated. The risk-benefit ratio might still favour rituximab in vaccinated patients with severe rheumatic and musculoskeletal diseases who have few other treatment options. Increased vigilance is needed in the presence of comorbidities and hypogammaglobulinaemia for all infection types.Wellcome Trust and Eli Lilly." @default.
• W4315433651 created "2023-01-11" @default.
• W4315433651 creator A5001888741 @default.
• W4315433651 creator A5014541038 @default.
• W4315433651 creator A5023290270 @default.
• W4315433651 creator A5026797171 @default.
• W4315433651 creator A5038444798 @default.
• W4315433651 creator A5068637534 @default.
• W4315433651 creator A5077962430 @default.
• W4315433651 creator A5088751978 @default.
• W4315433651 date "2023-02-01" @default.
• W4315433651 modified "2023-10-18" @default.
• W4315433651 title "Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study" @default.
• W4315433651 cites W1967360492 @default.
• W4315433651 cites W2004348520 @default.
• W4315433651 cites W2010937399 @default.
• W4315433651 cites W2039624081 @default.
• W4315433651 cites W2089863875 @default.
• W4315433651 cites W2143000096 @default.
• W4315433651 cites W2192934769 @default.
• W4315433651 cites W2737674906 @default.
• W4315433651 cites W2947252334 @default.
• W4315433651 cites W3034858522 @default.
• W4315433651 cites W3112369019 @default.
• W4315433651 cites W3124810175 @default.
• W4315433651 cites W3144879873 @default.
• W4315433651 cites W3164069651 @default.
• W4315433651 cites W3164519882 @default.
• W4315433651 cites W3184498267 @default.
• W4315433651 cites W3190398149 @default.
• W4315433651 cites W3197081215 @default.
• W4315433651 cites W3197504359 @default.
• W4315433651 cites W3200967734 @default.
• W4315433651 cites W3210988549 @default.
• W4315433651 cites W4200262223 @default.
• W4315433651 cites W4200519983 @default.
• W4315433651 cites W4206774631 @default.
• W4315433651 cites W4206949255 @default.
• W4315433651 cites W4220770181 @default.
• W4315433651 cites W4223656268 @default.
• W4315433651 cites W4229450998 @default.
• W4315433651 cites W4281625677 @default.
• W4315433651 cites W4283833956 @default.
• W4315433651 cites W4284671988 @default.
• W4315433651 cites W4294631385 @default.
• W4315433651 cites W4296293045 @default.
• W4315433651 cites W4297819665 @default.
• W4315433651 doi "https://doi.org/10.1016/s2665-9913(23)00004-8" @default.
• W4315433651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36712951" @default.
• W4315433651 hasPublicationYear "2023" @default.
• W4315433651 type Work @default.
• W4315433651 citedByCount "9" @default.
• W4315433651 countsByYear W43154336512023 @default.
• W4315433651 crossrefType "journal-article" @default.
• W4315433651 hasAuthorship W4315433651A5001888741 @default.
• W4315433651 hasAuthorship W4315433651A5014541038 @default.
• W4315433651 hasAuthorship W4315433651A5023290270 @default.
• W4315433651 hasAuthorship W4315433651A5026797171 @default.
• W4315433651 hasAuthorship W4315433651A5038444798 @default.
• W4315433651 hasAuthorship W4315433651A5068637534 @default.
• W4315433651 hasAuthorship W4315433651A5077962430 @default.
• W4315433651 hasAuthorship W4315433651A5088751978 @default.
• W4315433651 hasBestOaLocation W43154336511 @default.
• W4315433651 hasConcept C120665830 @default.
• W4315433651 hasConcept C121332964 @default.
• W4315433651 hasConcept C126322002 @default.
• W4315433651 hasConcept C167135981 @default.
• W4315433651 hasConcept C187212893 @default.
• W4315433651 hasConcept C201903717 @default.
• W4315433651 hasConcept C203014093 @default.
• W4315433651 hasConcept C2779123688 @default.
• W4315433651 hasConcept C2779134260 @default.
• W4315433651 hasConcept C2779338263 @default.
• W4315433651 hasConcept C2780653079 @default.
• W4315433651 hasConcept C3008058167 @default.
• W4315433651 hasConcept C50382708 @default.
• W4315433651 hasConcept C524204448 @default.
• W4315433651 hasConcept C61511704 @default.
• W4315433651 hasConcept C71924100 @default.
• W4315433651 hasConcept C72563966 @default.
• W4315433651 hasConceptScore W4315433651C120665830 @default.
• W4315433651 hasConceptScore W4315433651C121332964 @default.
• W4315433651 hasConceptScore W4315433651C126322002 @default.
• W4315433651 hasConceptScore W4315433651C167135981 @default.
• W4315433651 hasConceptScore W4315433651C187212893 @default.
• W4315433651 hasConceptScore W4315433651C201903717 @default.
• W4315433651 hasConceptScore W4315433651C203014093 @default.
• W4315433651 hasConceptScore W4315433651C2779123688 @default.
• W4315433651 hasConceptScore W4315433651C2779134260 @default.
• W4315433651 hasConceptScore W4315433651C2779338263 @default.
• W4315433651 hasConceptScore W4315433651C2780653079 @default.
• W4315433651 hasConceptScore W4315433651C3008058167 @default.
• W4315433651 hasConceptScore W4315433651C50382708 @default.
• W4315433651 hasConceptScore W4315433651C524204448 @default.
• W4315433651 hasConceptScore W4315433651C61511704 @default.
• W4315433651 hasConceptScore W4315433651C71924100 @default.
• W4315433651 hasConceptScore W4315433651C72563966 @default.
• W4315433651 hasFunder F4320307758 @default.

• next